DIFFERENCES IN THE VALUE OF BLOOD UREA NITROGEN AND CREATININE SERUM IN CERVICAL CANCER SQUAMOUS CELL STADIUM IIB-IIIB BEFORE AND AFTER CHEMOTHERAPY PACLITAXEL CISPLATIN FOR SIX CYCLES IN SANGLAH GENERAL HOSPITAL DENPASAR, BALI

Objective: The combination of paclitaxel-cisplatin regimen is one of the chemotherapy regimens used at Sanglah General Hospital, Denpasar. Cisplatin is a potent chemotherapeutic agent, but the nephrotoxic effects of cisplatin reported that research is needed to see the toxic effect on the kidneys before and after 6 series of paclitaxel-cisplatin chemotherapy. Toxicity assessment of the chemotherapy can be observed by evaluating kidney function from monitoring both blood urea nitrogen (BUN) and creatinine serum value. Methods: The research was conducted as an observational study using a prospective cohort method. The research was conducted from January 2016 to June 2016. Patients’ follow-up was conducted from the first until the last series of chemotherapy. The data were statistically analyzed with STATA version 14 with paired t-test when the data were normally distributed or the data were analyzed with Wilcoxon test when they were not normally distributed. Results: A total of seven patients were evaluated with both their BUN and creatinine serum values during six series of chemotherapy. Statistically, the BUN and creatinine serum values before the first and after the last paclitaxel-cisplatin chemotherapy series are not statistically significantly different (p>0.05). Conclusion: There are no significant changes of both BUN and creatinine serum values before the first and after the last paclitaxel-cisplatin chemotherapy series in patients with stadium IIB-IIIB squamous cell cervical cancer. Research with larger sample size is essential to provide optimal information for other health-care professionals. Keywords: Cervical cancer, Paclitaxel-cisplatin, Creatinine serum, Blood urea nitrogen.